Last year was rough. The pandemic mixed with lockdown measures cost the global economy USD$11.7 trillion dollars before Christmas and set the world on edge. Since the first shoe dropped in Wuhan late 2019, researchers have worked around the clock developing rapid-tests and vaccines. In this higher pursuit, PredictMedix (PMED.C), a Canadian-based developer of Healthcare AI solutions, created a non-invasive real time screening system for impairments like drugs and alcohol as well as infectious diseases like Covid.

May 2020, just four weeks out of the public market gate, PMED, signed two partnerships with multi-billion-dollar companies to provide its cannabis & alcohol impairment detection technology. Investors were excited. Now that vaccines are coming on line, investors are asking what PMED will be in a post-covid world. Equity.Guru’s own Chris Parry spoke with PMED COO and director, Dr. Rahul Kushwah, to give those questions a voice in a no-holds-barred interview. Tune in!

Full disclosure: PredictMedix is an Equity.Guru marketing client